St. Louis, Feb. 11, 1998 -- Washington University in St. Louis signed an agreement today with SIGA Pharmaceuticals Inc. that gives the company exclusive rights to new antibacterial technology. The agreement will allow SIGA to develop an entirely new class of antibiotics that are less likely to be sidelined by bacterial resistance than current therapies. It also provides three years of research funding to the Washington University scientists who are involved in this project.
The above story is based on materials provided by Washington University In St. Louis. Note: Materials may be edited for content and length.
Cite This Page: